Free digital starter kit

Text "CYR" to 85099 to download your free kit to help you get started on CYRAMZA.

Lilly Support Services^™: Support and Reimbursement.

Lilly Support Services^™ strives to offer reliable and individualized treatment support for eligible patients prescribed a Lilly Oncology product whether they are insured, underinsured, or simply uninsured. Services include help with benefits verification, prior Authorization support, specialty pharmacy coordination, access, reimbursement, and more.

For more information about Lilly Support Services^™, call 1-800-LillyRx(1-800-545-5979).

Eligible, commercially insured covered patients may qualify for Savings Card assistance.

Paying for treatment shouldn't be an additional concern for your loved ones, so we've created the Lilly Oncology Infused Products Savings Card Program, which may help you manage treatment costs.

Pay as little as $25 a month^* when eligible and commercially insured with coverage for Cyramza

^*Month is defined as 28 days

Governmental beneficiaries excluded. Eligibility required, terms and conditions apply. Savings subject to monthly and annual limits. Card eligibility and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. PROGRAM IS NOT INSURANCE. Review full terms and conditions at https://cyramza.lilly.com/financial-support#terms-and-conditions .
See below for Full terms and conditions.

Step 1: Eligible, commercially insured covered patients can download and print the savings card application

Government beneficiary excluded, T&Cs apply.

Download application

Step 2: Complete the patient portion of the application and take it to your physician

Step 3: Your physician will complete their section and return the application to Lilly Support Services^™ for processing

By enrolling in the Lilly Oncology Infused Products Savings Card Program ("Program") and using the Lilly Oncology Infused Products Savings Card ("Card"), you attest that you meet the eligibility criteria, agree to, and will comply with the terms and conditions described below:

Eligibility:

You have been prescribed one of the following Lilly Oncology medicines ("Covered Medicine") for an approved use consistent with FDA-approved product labeling: Cyramza^® (ramucirumab) or Erbitux^® (cetuximab);
You are enrolled in a commercial drug insurance plan and have coverage for your prescribed Covered Medicine, but your insurance does not cover the full cost of your prescribed Covered Medicine (i.e., you have a co-pay or coinsurance obligation);
You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE^®/CHAMPUS, or any state prescription drug assistance program;
You are a resident of the United States or Puerto Rico; and
You are 18 years of age or older.

Card Terms and Conditions
You must (a) have commercial drug insurance that covers your prescribed Covered Medicine, but your insurance does not cover the full cost and (b) have a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $25 for each infusion of your prescribed Covered Medicine. The Program will cover your co-pay or coinsurance for your prescribed Covered Medicine less $25, up to a maximum monthly savings of up to wholesale acquisition cost plus usual and customary fees and a separate maximum annual savings of up to $25,000 per calendar year. Card may be used for a maximum of up to 12 infusions per calendar year. After the monthly and/or annual maximum savings are reached, you will be responsible for paying any remaining monthly/annual out-of-pocket costs. Program may provide support for infusions with a date of service that falls within 120 days prior to the date the enrollment form is received by the Program.

To receive Program savings, your healthcare provider must submit a claim for coverage to your medical insurance provider. If your medical insurance provider does not cover the full cost of the claim, your healthcare provider must then submit an Explanation of Benefits (EOB) form and a CMS 1450 or 1500 form to www.LillyOncologyPortal.com within 180 days of the infusion date of your prescribed Covered Medicine. The submitted form must include the name of the insurer and plan and demonstrate that a Covered Medication was the medication administered. You understand and agree that Lilly will make a payment of your Program savings on your behalf to your healthcare provider. Subject to Lilly USA, LLC's ("Lilly") right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

Additional Terms and Conditions
If you have an insurance plan that is participating in an alternate funding program ("AFP") that requires you to apply to the Lilly Oncology Infused Products Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of your prescribed Covered Medicine, you are not eligible for and are prohibited from using the Lilly Oncology Infused Products Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly Products from coverage contingent upon a member's use of the Lilly Oncology Infused Products Savings Card Program. You agree to inform the Lilly Oncology Infused Products Savings Card Program if you are or become a member of such an alternate funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum savings. Monthly and annual maximums are set at Lilly's sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for your prescribed Covered Medicine, only allows partial coverage for your prescribed Covered Medicine, removes coverage for your prescribed Covered Medicine and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of your prescribed Covered Medicine, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for your prescribed Covered Medicine.

Program savings are limited to the co-pay or coinsurance costs for your prescribed Covered Medicine only, subject to monthly and annual maximum savings, outlined above. The Program will not cover, and shall not be applied toward, the cost of any dosing procedure, any other healthcare provider service or supply charges or other treatment costs, or any costs associated with a hospital stay. Participation in the Program requires a valid patient HIPAA authorization to enroll in the Program. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Lilly Oncology Infused Products Savings Card Program and agree to call Lilly Support Services for Oncology Infused Products at 1-800-545-5979 to stop participation. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving your prescribed Covered Medicine. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are non-transferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly's sole discretion to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card's eligibility criteria or is using or has attempted to use the Card inconsistently with these Terms and Conditions. Eligibility criteria, and terms and conditions for the Lilly Oncology Infused Products Savings Card Program may change from time to time; the most current version can be found at https://cyramza.lilly.com/financial-support#terms-and-conditions . You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly USA, LLC's right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

TRICARE^® is a registered trademark of the Department of Defense (DoD), DHA.

Other resources

When insurance isn't enough to pay for treatment or you have no insurance, there are other resources that may help with your financial challenges to get the medication you need.

Lilly Cares^® Foundation

The Lilly Cares Foundation, Inc., a separate nonprofit organization, offers a patient assistance program to help qualifying patients receive Lilly medications at no cost. For more information about Lilly Cares, please visit LillyCares.com.

Independent Patient-Assistance Program Foundations

Lilly Support Services provides information about a number of independent patient-assistance programs that may be able to help underinsured patients get the treatment they need with less financial stress. These foundations are not affiliated with Eli Lilly and Company and are operated independently. Funding availability changes weekly, so contact Lilly Support Services at 1-800-LillyRx (1-800-545-5979) for the most recent updates.

View Foundation List

SAFETY SUMMARY

Warnings -

Serious side effects include:

Severe bleeding, including bleeding in the stomach or bowel, has happened with CYRAMZA. This can be life threatening. If severe bleeding happens, you will have to stop receiving CYRAMZA.
Tears in the stomach or bowel wall may happen with CYRAMZA. This can be life threatening. If you have tears in the stomach or bowel wall, you will have to stop receiving CYRAMZA.
Wounds may not heal quickly or completely. If you are having surgery, CYRAMZA treatment should be stopped beforehand. Your doctor may put you back on CYRAMZA after your surgical wound has healed.
Strokes, mini-strokes, blood clots, and heart attacks have happened to people on CYRAMZA. These can be fatal. If you have one of these events, you will have to stop receiving CYRAMZA.
Severe high blood pressure has happened with CYRAMZA. Your doctor will take your blood pressure at least every two weeks while you are receiving CYRAMZA. Depending on your blood pressure, your doctor may pause or permanently stop CYRAMZA.
Reactions related to infusing CYRAMZA have happened. These can be severe and life threatening. Most of these reactions happened during or after the first or second CYRAMZA infusion. In severe reactions, rapid heartbeat, low blood pressure, and severe trouble breathing may happen. Your health care team will give you medicine before each CYRAMZA infusion and will watch you for these side effects. If a reaction happens, CYRAMZA treatment may be infused at a slower rate or may be permanently stopped, depending on how severe the reaction is.
CYRAMZA may worsen certain types of liver disease.
A very rare but serious brain disorder has been found in research trials with CYRAMZA. The disorder is called PRES (posterior reversible encephalopathy syndrome). Signs of PRES may include seizure, headache, nausea, vomiting, blindness, and changes in your thinking. These symptoms may stop or improve within days. However, the changes in thinking can be ongoing, and PRES can be fatal. If you develop PRES, you will have to stop receiving CYRAMZA.
Too much protein in the urine (called proteinuria) has been found in research trials with CYRAMZA. This may be a sign of kidney damage. Your doctor will watch your urine protein levels during treatment. If you develop protein in your urine, your doctor may pause your treatment and lower your dose of CYRAMZA. If you have severe proteinuria, you will have to stop receiving CYRAMZA permanently.
Thyroid gland problems have been found in research trials with CYRAMZA. Your doctor will do blood tests to track how well your thyroid gland works during treatment.
CYRAMZA can harm your unborn baby. You should avoid getting pregnant, and use effective birth control while receiving CYRAMZA and for 3 months after your last dose.
CYRAMZA may harm a breastfeeding child. Do not breastfeed your child during treatment with CYRAMZA and for 2 months after your last dose.

Tell your doctor right away if you have:

Bleeding or symptoms of bleeding, including lightheadedness.
Severe diarrhea, vomiting, or severe abdominal pain.
A wound that doesn’t heal properly or have a surgery planned.
High blood pressure or symptoms of high blood pressure, including severe headache or lightheadedness or confusion, changes in your vision, or seizure.
Symptoms of infusion reactions, including:
- Shaking or stiffness of the body
- Back pain or spasms
- Chest pain or tightness
- Chills
- Flushing (sudden warmth and/or reddened skin on the face, neck, or upper chest)
- Difficulty breathing
- Wheezing (a whistling sound in the breath caused by narrowed breathing tubes)
- Becoming blue due to lack of oxygen
- Tingling or numbness of the skin
Had liver disease or other liver problems.
Symptoms of PRES, including seizure, headache, nausea or vomiting, or changes in vision or thinking.

Common side effects

The most common side effects of CYRAMZA when given by itself include:

Low blood platelet count
Feeling tired
Low albumin (protein in the blood)
Low sodium in the blood
Swelling in the arms, legs, hands, or feet
High blood pressure
Stomach pain
Low white blood cell count
Not feeling hungry
Too much protein in the urine
Feeling like you want to throw up (vomit)
Unusual buildup of fluid in the belly
Low calcium in the blood
Headache
Diarrhea
Nose bleeds
Trouble falling or staying asleep
Fever
Vomiting
Back Pain

The most common serious side effects of CYRAMZA when given by itself include:

Anemia (a decrease in red blood cells)
Blocked digestive tract

Unusual buildup of fluid in the belly
Pneumonia (infection of one or both lungs)

Some people needed to have extra red blood cells put into their blood.

The most common side effects of CYRAMZA when given with certain chemotherapy medicines include:

Low white blood cell count
Diarrhea
Tiredness
Mouth sores with or without swelling in the lining of the mouth
Decreased appetite
Nose bleeds
Low blood platelet count
High blood pressure
Swelling in the arms, legs, hands, or feet
Too much protein in the urine
Low white blood cell count with a fever
Swelling, redness, or pain in the palms or soles (hand-foot syndrome)
Increased production of tears
Bleeding in the digestive tract
Low albumin (a protein in the blood)

The most common serious side effects of CYRAMZA when given with certain chemotherapy medicines include:

Low white blood cell count with a fever
Pneumonia
Low white blood cell count

Diarrhea
Blocked digestive tract

Some people needed treatment to increase their white blood cell counts.

The most common side effects of CYRAMZA when given with erlotinib include:

Infections
Increased levels of liver enzymes
Diarrhea
High blood pressure
Low red blood cell count
A sore or inflammation inside the mouth
Low blood platelet count
Loss of hair
Nosebleeds

Too much protein in the urine
Decrease in a type of white blood cell
Low potassium in the blood
Swelling in the arms, legs, hands, and feet
Headache
Gastrointestinal bleeding
Gums bleeding
Bleeding in the lungs or respiratory tract

The most common serious side effects of CYRAMZA when given with erlotinib include:

Pneumonia (infection in one or both lungs)
Skin infection (bacterial infection under the skin)
Collapsed lung (air or other gas in the pleural cavity in the lungs)

Some people needed to have extra red blood cells put into their blood.

These are not all the possible side effects of CYRAMZA. Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using

Before you receive CYRAMZA, tell your doctor if you:

Have had or are at high risk for strokes or heart attack.
Have high blood pressure or have blood pressure problems.
Are planning to have surgery of any kind.
Have ever had liver problems, including cirrhosis or other diseases of the liver.
Are pregnant or may be pregnant: CYRAMZA can harm your unborn baby. You should avoid getting pregnant and use effective birth control during treatment with CYRAMZA and for 3 months after the last dose.
Are breastfeeding: Your doctor will tell you to stop breastfeeding during treatment with CYRAMZA and for 2 months after the last dose.

Also tell your doctor about all the medicines and supplements you take, whether they have been prescribed for you or you buy them without a prescription.

How to take

CYRAMZA is given by intravenous (IV) infusion. The infusion will last 60 minutes. If you handle the first infusion of CYRAMZA well, then your next infusions may only take 30 minutes. The schedule for receiving CYRAMZA depends on what type of cancer you are being treated for. These are typical schedules:
- Once every 2 weeks for stomach cancer or GE junction cancer that is advanced or has spread to other parts of the body, colorectal cancer that has spread to other parts of the body, hepatocellular carcinoma that has AFP levels of at least 400 ng/mL or higher, or when used with the targeted therapy, erlotinib, for certain types of EGFR mutation positive non-small cell lung cancer that has spread to other parts of the body.
- Once every 3 weeks, when used with the chemotherapy, docetaxel, for non-small cell lung cancer that has spread to other parts of the body.
Your doctor will give you other medicines before your CYRAMZA infusion to help lower the chance of an infusion reaction.

Learn more

CYRAMZA is a prescription medicine. For more information, call 1-800-545-5979.

This summary provides basic information about CYRAMZA but does not include all information known about this medicine. Read the information given to you about CYRAMZA. This information does not take the place of talking with your doctor. Your doctor is the best person to help you decide if CYRAMZA is right for you.

RB CON BS 30APR2025

CYRAMZA^® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

INDICATIONS

CYRAMZA^® (sigh-RAM-zuh) is a medicine used to treat certain types of cancer and is prescribed in these ways:

By itself or with a chemotherapy medicine called paclitaxel for adults to treat certain kinds of stomach cancer, or cancer of the area where the stomach and esophagus (food pipe) meet that is advanced or has spread to other parts of the body. The area where the stomach and esophagus meet is often called the gastroesophageal (GE) junction. CYRAMZA is for people whose stomach cancer got worse during or after certain other types of chemotherapy.
With a chemotherapy medicine called docetaxel for adults to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and has gotten worse during or after another type of chemotherapy. People who have tumors with certain abnormal genes should not receive CYRAMZA unless they have already been treated with medicine that targets those changes and their cancer became worse during treatment.
With a combination of chemotherapy medicines called FOLFIRI (irinotecan, folinic acid, and fluorouracil). This is given to treat colorectal cancer (CRC) in adults that has spread to other parts of the body and has gotten worse during or after certain other types of chemotherapy.
By itself to treat a type of liver cancer called hepatocellular carcinoma (HCC). CYRAMZA is for adults who have levels of alpha-fetoprotein of at least 400 nanograms per milliliter (ng/mL) in their blood and have been treated with another type of chemotherapy medicine called sorafenib.
For adults in combination with another medicine called erlotinib as a first-line treatment for certain types of EGFR mutation positive non-small cell lung cancer (NSCLC) that has spread to other parts of the body.

It is not known if CYRAMZA is safe and effective in children.

CYRAMZA is given by intravenous (IV) infusion. An IV infusion is when a needle is placed into your vein and a medicine is given slowly.